JP7688690B2 - ピリミジン系化合物の塩、結晶形およびその調製方法 - Google Patents

ピリミジン系化合物の塩、結晶形およびその調製方法 Download PDF

Info

Publication number
JP7688690B2
JP7688690B2 JP2023503101A JP2023503101A JP7688690B2 JP 7688690 B2 JP7688690 B2 JP 7688690B2 JP 2023503101 A JP2023503101 A JP 2023503101A JP 2023503101 A JP2023503101 A JP 2023503101A JP 7688690 B2 JP7688690 B2 JP 7688690B2
Authority
JP
Japan
Prior art keywords
compound
crystalline form
salt
fumarate
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023503101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535361A (ja
JP2023535361A5 (cg-RX-API-DMAC7.html
Inventor
ゴン,ヂァン
リー,ホンミン
イー,シードン
リー,ロン
ワン,ティアンミン
チェン,ピンユン
ヤン,チェンシー
ワン,タオ
ソン,ヤオヤオ
ヂョウ,ジァンフェン
リァン,ユーフォン
チェン,ヂョンフイ
ティアン,チアン
ソン,ホンメイ
シュ,トントン
ワン,ジンイー
Original Assignee
スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド filed Critical スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド
Publication of JP2023535361A publication Critical patent/JP2023535361A/ja
Publication of JP2023535361A5 publication Critical patent/JP2023535361A5/ja
Application granted granted Critical
Publication of JP7688690B2 publication Critical patent/JP7688690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023503101A 2020-07-28 2021-07-23 ピリミジン系化合物の塩、結晶形およびその調製方法 Active JP7688690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010737039.7 2020-07-28
CN202010737039 2020-07-28
PCT/CN2021/108032 WO2022022398A1 (zh) 2020-07-28 2021-07-23 一种嘧啶类化合物的盐和晶型及其制备方法

Publications (3)

Publication Number Publication Date
JP2023535361A JP2023535361A (ja) 2023-08-17
JP2023535361A5 JP2023535361A5 (cg-RX-API-DMAC7.html) 2024-07-29
JP7688690B2 true JP7688690B2 (ja) 2025-06-04

Family

ID=80037147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503101A Active JP7688690B2 (ja) 2020-07-28 2021-07-23 ピリミジン系化合物の塩、結晶形およびその調製方法

Country Status (7)

Country Link
US (1) US12630557B2 (cg-RX-API-DMAC7.html)
EP (1) EP4190781A4 (cg-RX-API-DMAC7.html)
JP (1) JP7688690B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230044358A (cg-RX-API-DMAC7.html)
CN (1) CN115702154B (cg-RX-API-DMAC7.html)
BR (1) BR112023000065A2 (cg-RX-API-DMAC7.html)
WO (1) WO2022022398A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120897743A (zh) * 2023-05-19 2025-11-04 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与ret基因改变相关疾病的用途和方法
WO2026017002A1 (zh) * 2024-07-16 2026-01-22 四川科伦博泰生物医药股份有限公司 以杂环化合物为活性成分的药物组合物、其制备方法及用途
GB202410599D0 (en) 2024-07-19 2024-09-04 Ellipses Pharma Ltd Therapeutics useful synergistic combinations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111285882A (zh) 2018-12-07 2020-06-16 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
WO2020168939A1 (zh) 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 杂环化合物、包含其的药物组合物及其制备方法和用途
WO2022199503A1 (zh) 2021-03-24 2022-09-29 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
BRPI0607062A2 (pt) 2005-02-28 2009-08-04 Japan Tobacco Inc composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
RU2363699C2 (ru) 2005-02-28 2009-08-10 Джапан Тобакко Инк. Новое производное аминопиридина с ингибиторной активностью в отношении syk.
CN101166734A (zh) 2005-02-28 2008-04-23 日本烟草产业株式会社 具有Syk抑制活性的新型的氨基吡啶化合物
EP1953153A1 (en) 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
US20080234267A1 (en) * 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
CN102812022B (zh) 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
JP2013107824A (ja) 2010-03-17 2013-06-06 Dainippon Sumitomo Pharma Co Ltd 新規単環ピリミジン誘導体
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
WO2012057262A1 (ja) 2010-10-28 2012-05-03 日本新薬株式会社 ピリジン誘導体及び医薬
WO2012154518A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
JP6535430B2 (ja) 2012-09-28 2019-06-26 イグニタ、インク. 非定型プロテインキナーゼcのアザキナゾリン阻害薬
EA031505B1 (ru) 2014-12-02 2019-01-31 Прана Байотекнолоджи Лимитед СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
WO2017146186A1 (ja) 2016-02-26 2017-08-31 塩野義製薬株式会社 Ampk活性化作用を有する5-フェニルアザインドール誘導体
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
WO2018011169A1 (en) 2016-07-12 2018-01-18 Laboratorios Del Dr. Esteve, S.A. Use of sigma receptor ligands in post-herpetic pain
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ucb製藥有限公司 吡啶基及吡基-(氮)吲哚磺醯胺
WO2020035065A1 (zh) 2018-08-17 2020-02-20 南京明德新药研发有限公司 作为ret抑制剂的吡唑衍生物
WO2020083332A1 (zh) 2018-10-24 2020-04-30 南京明德新药研发有限公司 作为ret抑制剂的嘧啶衍生物
WO2020083311A1 (zh) 2018-10-24 2020-04-30 南京明德新药研发有限公司 作为ret抑制剂的吡嗪衍生物
JP7347853B2 (ja) 2018-12-06 2023-09-20 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピラゾロ[1,5-a]ピリジン化合物、該化合物を含む組成物およびその使用
WO2020114474A1 (zh) 2018-12-06 2020-06-11 苏州信诺维医药科技有限公司 一种杂环化合物、其应用及含其的药物组合物
CN111484479B (zh) 2019-01-25 2023-06-13 四川科伦博泰生物医药股份有限公司 氮杂环化合物、包含其的药物组合物及其制备方法和用途
CN111499613B (zh) 2019-01-31 2023-05-12 浙江海正药业股份有限公司 N-甲酰胺衍生物、其制备方法及其在医药上的用途
KR102689665B1 (ko) 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
CN111606886A (zh) 2019-02-25 2020-09-01 察略盛医药科技(上海)有限公司 吡唑类衍生物、其制备方法及其在医药上的用途
WO2020175968A1 (ko) 2019-02-28 2020-09-03 주식회사 보로노이 N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 약학적 조성물
JP7198386B2 (ja) 2019-04-03 2022-12-28 広州白雲山医薬集団股分有限公司白雲山制薬総廠 Ret阻害剤としての窒素含有スピロ環誘導体
CN111808077B (zh) 2019-04-12 2023-05-02 浙江海正药业股份有限公司 哌嗪酰胺衍生物,其制备方法及其在医药上的用途
CN111961034A (zh) 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
MX2021014273A (es) 2019-05-21 2022-01-06 Voronoi Inc Derivado de heteroarilo que contiene n y composicion farmaceutica que lo comprende como principio activo para la prevencion o el tratamiento de cancer.
US12275694B2 (en) 2019-05-24 2025-04-15 Irl 790 Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
WO2020242946A1 (en) 2019-05-24 2020-12-03 Fmc Corporation Pyrazole-substituted pyrrolidinones as herbicides
CN113490670B (zh) 2019-08-05 2023-06-02 北京志健金瑞生物医药科技有限公司 含氮多环稠环类化合物,其药物组合物、制备方法和用途
CN112574201B (zh) 2019-09-29 2024-04-19 四川科伦博泰生物医药股份有限公司 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
CN113135896B (zh) 2020-01-18 2024-12-06 正大天晴药业集团股份有限公司 作为ret抑制剂的甲基吡唑类衍生物
CN112279836B (zh) 2020-12-29 2021-04-30 北京鑫开元医药科技有限公司 一种n-(5-甲基-1h-吡唑-3-基)吡啶-2-胺类化合物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111285882A (zh) 2018-12-07 2020-06-16 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
WO2020168939A1 (zh) 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 杂环化合物、包含其的药物组合物及其制备方法和用途
WO2022199503A1 (zh) 2021-03-24 2022-09-29 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Also Published As

Publication number Publication date
CN115702154A (zh) 2023-02-14
EP4190781A4 (en) 2023-12-27
US20230295174A1 (en) 2023-09-21
BR112023000065A2 (pt) 2023-01-31
CN115702154B (zh) 2026-07-17
US12630557B2 (en) 2026-05-19
EP4190781A1 (en) 2023-06-07
JP2023535361A (ja) 2023-08-17
KR20230044358A (ko) 2023-04-04
WO2022022398A1 (zh) 2022-02-03

Similar Documents

Publication Publication Date Title
AU2020220512B2 (en) FGFR inhibitor compound in solid form and preparation method therefor
CN105377835B (zh) 酪氨酸蛋白激酶调节剂及其应用方法
JP6986032B2 (ja) Jak阻害剤としてのピロロピリミジン化合物の結晶
KR101787784B1 (ko) 3-(2,6―디클로로―3,5―디메톡시―페닐)-1-{6-[4-(4-에틸-피페라진-1-일)-페닐아미노]-피리미딘-4-일}-1-메틸-우레아의 결정질 형태 및 그의 염
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
US11629153B2 (en) Forms and compositions of a MK2 inhibitor
US12630557B2 (en) Salt and crystal form of pyrimidine compound, and preparation methods therefor
CN115175902A (zh) 一类用作激酶抑制剂的化合物及其应用
WO2016201280A1 (en) Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
JP2025094218A (ja) Jak2阻害剤の結晶形態
US20240174669A1 (en) Crystalline forms of a parp1 inhibitor
JP2023536892A (ja) Jak阻害剤化合物及びその使用
KR20250130412A (ko) 화합물 a의 염과 결정형, 및 그 제조 방법과 용도
JP6974618B2 (ja) Fgfr及びvegfr阻害剤としての化合物の塩形態、結晶形およびその製造方法
WO2019096112A1 (zh) 一种取代的苯并咪唑化合物及包含该化合物的组合物
WO2021063335A1 (zh) Erk1/2蛋白激酶抑制剂及其用途
CN114026088A (zh) Jak2抑制剂的结晶形式
US20240287045A1 (en) Crystal form of pyrimidine derivative and preparation method therefor
CN115397827B (zh) Fgfr4抑制剂的盐型、晶型及其用途
CN117800954A (zh) 杂环化合物及其应用
CN108430987A (zh) Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
JP2023543080A (ja) ピロロ複素環系誘導体の結晶及びその製造方法
HK40083712A (en) Salt and crystal form of pyrimidine compound, and preparation methods therefor
JP2023531078A (ja) 化合物の結晶形態
CN114075135B (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250501

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250523

R150 Certificate of patent or registration of utility model

Ref document number: 7688690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150